Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes

Author(s):
Reichardt, P.; Demetri, G.D.; Jeffers, M.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.G.; Mehren, M. von; Joensuu, H.; Badalamenti, G.; Blackstein, M.E.; Cesne, A. le; Schoffski, P.; Maki, R.G.; Xu, J.M.; Nishida, T.; Kuss, I.; Casali, P.G.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-02-28
Language
English
Is part of
Oncology Research and Treatment (2014), Vol. 37, p. 58-58
hdl
1887/104666